Rigel Pharmaceuticals, Inc.

RIGL Healthcare Biotechnology

Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024. In the quarter to June 2026, revenue fell 22.6%, EPS fell 72.1%, free cash flow fell 230.0% and total debt fell 66.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

45.97 1.28 −2.71%
Market cap
$882.6M
P/E
2.6×
Fwd P/E
7.9×
Dividend yield
—
F-score
6/9
Altman Z
2.70
Beneish M
0.78
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
154.96 77.32 56.93 58.21 124.97 57.33 98.08 128.54 115.75 74.77
Receivables
51.76 41.62 30.55 40.32 15.47 15.97 10.11 4.08 — —
Inventory
11.51 6.00 5.52 9.12 6.62 1.64 1.35 0.89 — —
Total current assets
240.17 135.10 99.27 115.90 154.47 88.98 119.01 136.99 117.43 76.21
Property, Plant, Equpment (Net)
— 0.09 0.17 0.86 2.18 2.68 2.16 1.39 0.88 1.16
Goodwill and Intangible Assets (Total)
24.75 27.10 13.88 14.95 — — — — — —
Long Term Assets (Tax, Deferred)
245.85 — — — — — — — — —
Long-term assets (Other)
1.91 1.53 3.06 0.64 0.97 0.82 0.70 0.74 0.80 0.76
Total non-current assets
273.43 28.87 17.96 18.38 12.86 21.40 28.56 2.12 1.68 1.92
Total Assets
513.59 163.98 117.23 134.28 167.33 110.38 147.57 139.11 119.11 78.13
Notes Payable
29.81 7.27 7.23 — — — — — — —
Accounts Payable
7.19 3.34 7.14 22.51 3.80 3.71 4.15 6.39 2.64 5.56
Accrued Expenses
17.44 14.21 12.19 16.57 21.07 14.48 14.78 16.72 12.09 9.97
Current Part of Capital Lease
— — — — — — — — 0.28 3.22
Current Revenue (Deferred)
— 1.36 1.36 1.37 2.60 3.02 25.29 1.03 — 2.80
Other current liabilities
44.18 38.19 19.33 17.14 21.42 28.51 46.79 21.34 15.70 17.03
Total current liabilities
99.24 63.30 53.27 65.21 63.55 40.84 58.21 27.73 18.34 22.59
Long Term Debt (Total)
22.48 52.41 52.37 39.45 19.91 19.82 9.81 — — 0.24
Non-current Revenue (Deferred)
— — — — — — 1.40 1.50 0.09 0.28
Non-current Liabilities (Other)
— 44.98 39.94 42.26 52.73 5.05 5.10 1.50 0.04 0.00
Total non-current liabilities
22.88 97.39 92.60 82.68 73.40 35.51 35.54 1.50 0.13 0.52
Total liabilities
122.11 160.69 145.87 147.90 136.95 76.35 93.75 29.23 18.47 23.11
Additional Paid In Capital
1,414.32 1,393.33 1,378.88 1,368.82 1,354.19 1,339.83 1,329.85 1,319.07 1,239.44 1,115.81
Common Stock (Net)
0.02 0.02 0.02 0.17 0.17 0.17 0.17 0.17 0.15 0.10
Retained Earnings
(1,023.04) (1,390.06) (1,407.55) (1,382.46) (1,323.89) (1,305.97) (1,276.23) (1,209.33) (1,138.85) (1,060.86)
Common Equity (Total)
391.48 3.29 (28.64) (13.62) 30.37 34.03 53.82 109.88 100.65 55.03
Shareholders Equity (Total)
391.48 3.29 (28.64) (13.62) 30.37 34.03 53.82 109.88 100.65 55.03
Shareholders Equity and Liabilities (Total)
513.59 163.98 117.23 134.28 167.33 110.38 147.57 139.11 119.11 78.13
Shares (Common)
18.31 17.71 17.48 17.34 17.16 16.93 16.80 16.72 14.68 9.93
Shareholders Equity (Tangible)
366.73 (23.81) (42.52) (28.56) 30.37 34.03 53.82 109.88 100.65 55.03
Net Debt
(132.47) (24.91) (4.56) (18.76) (105.05) (37.51) (88.27) (128.54) (115.75) (74.53)
Total Debt
22.48 52.41 52.37 39.45 19.91 19.82 9.81 — — 0.24

Fold the line items

In millions of $ except per-share values · columns are period end dates